Takeda adds oncolytic viruses to pipeline via Turnstone deal

Takeda has partnered with Turnstone to discover and develop immunotherapies using the biotech’s engineered vaccinia virus platform in a deal that gives the Japanese pharma its first oncolytic virus.

Turnstone Biologics Inc. will receive upfront and near-term milestone payments and an equity investment totaling

Read the full 436 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE